The trajectory of Viagra, initially marketed by copyright, presents a intricate case study for stakeholders considering the pharmaceutical arena . Although its initial success and impact of vast in sales, the patent lapse has opened the floodgates for generic medications, substantially diminishing earnings opportunities. This shift raises questions